Vancouver, British Columbia, November 9, 2021 – Global Wellness Strategies Inc. (CSE:GWS) (Frankfurt:O3X4) (OTCQB: PNNRF) (“Global” or the “Company”) updates on MDMA provisional patent applications.
Shanti Therapeutics has a filed provisional patent application for the treatment of pain with MDMA. Global Wellness hasacquired 100% of the share capital in Shanti Therapeutics and all its constituent intellectual property. Upon completion of the initial clinical trial, the provisional patent will be upgraded to a global PCT patent with USPTO coverage.
The Phase 2a clinical trial in healthy volunteers is scheduled to commence recruitment in Q1 2022 and has the dual purpose of calculating the effect size of the anti-nociceptive effect of MDMA as well as some dose guidance on what is the minimal effective dose to achieve the required anti- nociceptive effect without precipitating psychedelic symptoms.
Further intellectual property related to optimal dosing strategies, correct pre-surgical timing of MDMA administrationand knowledge of the most accurate modality for measurement of treatment effect will be captured during the course of this clinical trial.
Associate Professor Michael Keane and Dr Sud Agarwal have reviewed the finalized research protocol which is ready tobe shared with potential CRO and research site partners. Human Research Ethics Committee submission is on target forlate November 2021 with first patient in scheduled for Q1 2022.
“Being able to use a single preoperatively administered tablet to influence postoperative pain relief needs seemed like something out of science fiction movies. However, with the ever expanding knowledge around MDMA’s neuromodulating properties on areas of the brain responsible for reporting pain, this becomes a distinct possibility. Our acquisition at Global Wellness of Shanti is a game changer for our shareholders and hopefully all those who have suffered from chronic pain. We like to say at GWS we help people “Get Well Soon” said Meris Kott, CEO.
About Global Wellness Strategies
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational,and management assistance in the fast-growing market for wellness consumer products. The focus of the Company ison global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.
For further information visit websites:
www.globalwellnessstrategies.com and www.shantitherapeutics.com
Or Contact Meris Kott CEO 604.484.0355 or email to [email protected]
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similarCanadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certaincorporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions containedherein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.